Published in Trends Pharmacol Sci on November 28, 2005
Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. J Biol Chem (2009) 1.91
The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol (2007) 1.74
The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology (Berl) (2006) 1.72
Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia (2010) 1.70
The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci U S A (2009) 1.63
Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem (2009) 1.60
Novel cannabinoid receptors. Br J Pharmacol (2007) 1.55
Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem (2010) 1.49
Integrin clustering enables anandamide-induced Ca2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression. J Cell Sci (2008) 1.48
Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev Mol Med (2009) 1.44
Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. Br J Pharmacol (2007) 1.32
Cannabinoids in health and disease. Dialogues Clin Neurosci (2007) 1.28
GPR55: a new member of the cannabinoid receptor clan? Br J Pharmacol (2007) 1.27
The peripheral cannabinoid receptor knockout mice: an update. Br J Pharmacol (2007) 1.25
Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers. Br J Pharmacol (2007) 1.24
The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem (2007) 1.24
Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol Ther (2010) 1.24
Receptors for acylethanolamides-GPR55 and GPR119. Prostaglandins Other Lipid Mediat (2009) 1.23
Endocannabinoid-like N-arachidonoyl serine is a novel pro-angiogenic mediator. Br J Pharmacol (2010) 1.10
Endocannabinoids in the retina: from marijuana to neuroprotection. Prog Retin Eye Res (2008) 1.08
Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. Br J Pharmacol (2007) 1.07
Endocannabinoids and the gastrointestinal tract: what are the key questions? Br J Pharmacol (2007) 1.07
Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. Br J Pharmacol (2007) 1.05
Cannabinoid receptors: nomenclature and pharmacological principles. Prog Neuropsychopharmacol Biol Psychiatry (2012) 1.03
Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands. Br J Pharmacol (2007) 0.99
Modulation of fear and anxiety by the endogenous cannabinoid system. CNS Spectr (2007) 0.99
The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT). Biochem Pharmacol (2008) 0.98
Endocannabinoid system and synaptic plasticity: implications for emotional responses. Neural Plast (2007) 0.97
Anti-obesity efficacy of LH-21, a cannabinoid CB(1) receptor antagonist with poor brain penetration, in diet-induced obese rats. Br J Pharmacol (2012) 0.96
The therapeutic potential of novel cannabinoid receptors. Pharmacol Ther (2009) 0.95
Cellular and intracellular mechanisms involved in the cognitive impairment of cannabinoids. Philos Trans R Soc Lond B Biol Sci (2012) 0.95
Cannabinoid control of neuroinflammation related to multiple sclerosis. Br J Pharmacol (2007) 0.94
Endocannabinoids and the heart. J Cardiovasc Pharmacol (2009) 0.94
Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors. Cell Mol Neurobiol (2006) 0.93
Aspects of endocannabinoid signaling in periimplantation biology. Mol Cell Endocrinol (2008) 0.93
Lasting impacts of prenatal cannabis exposure and the role of endogenous cannabinoids in the developing brain. Future Neurol (2011) 0.92
Identification of the synthetic cannabinoid R(+)WIN55,212-2 as a novel regulator of IFN regulatory factor 3 activation and IFN-beta expression: relevance to therapeutic effects in models of multiple sclerosis. J Biol Chem (2011) 0.92
Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects. Front Behav Neurosci (2011) 0.91
Vasorelaxant effects of oleamide in rat small mesenteric artery indicate action at a novel cannabinoid receptor. Br J Pharmacol (2006) 0.90
A potential role for GPR55 in gastrointestinal functions. Curr Opin Pharmacol (2012) 0.90
Tuning the endocannabinoid system: allosteric modulators of the CB1 receptor. Br J Pharmacol (2007) 0.87
GPR55 and the vascular receptors for cannabinoids. Br J Pharmacol (2007) 0.86
Tempo and mode in the endocannaboinoid system. J Mol Evol (2007) 0.84
Modulation of sensory neuron potassium conductances by anandamide indicates roles for metabolites. Br J Pharmacol (2008) 0.83
The Endocannabinoid System in the Postimplantation Period: A Role during Decidualization and Placentation. Int J Endocrinol (2013) 0.83
What we know and do not know about the cannabinoid receptor 2 (CB2). Semin Immunol (2014) 0.81
A shifted repertoire of endocannabinoid genes in the zebrafish (Danio rerio). Mol Genet Genomics (2007) 0.81
Genetic background can result in a marked or minimal effect of gene knockout (GPR55 and CB2 receptor) in experimental autoimmune encephalomyelitis models of multiple sclerosis. PLoS One (2013) 0.81
Pharmacological profiling of the hemodynamic effects of cannabinoid ligands: a combined in vitro and in vivo approach. Pharmacol Res Perspect (2015) 0.80
Turning Over a New Leaf: Cannabinoid and Endocannabinoid Modulation of Immune Function. J Neuroimmune Pharmacol (2015) 0.80
Molecular Targets of Cannabidiol in Neurological Disorders. Neurotherapeutics (2015) 0.79
Endocannabinoids in cerebrovascular regulation. Am J Physiol Heart Circ Physiol (2016) 0.79
Cannabinoid receptor agonist protects cultured dopaminergic neurons from the death by the proteasomal dysfunction. Anat Cell Biol (2011) 0.79
Vascular pharmacology of a novel cannabinoid-like compound, 3-(5-dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-methyl-ethyl)benzamide (VSN16) in the rat. Br J Pharmacol (2007) 0.79
The Endocannabinoid System in the Retina: From Physiology to Practical and Therapeutic Applications. Neural Plast (2016) 0.78
GPR55 deletion in mice leads to age-related ventricular dysfunction and impaired adrenoceptor-mediated inotropic responses. PLoS One (2014) 0.78
Role of GPR55 during Axon Growth and Target Innervation(1,2,3). eNeuro (2015) 0.77
Intercellular Lipid Mediators and GPCR Drug Discovery. Biomol Ther (Seoul) (2013) 0.77
Pharmacological characterization of cannabinoid receptor activity in the rat-isolated ileum myenteric plexus-longitudinal muscle preparation. Br J Pharmacol (2010) 0.76
Endothelial atypical cannabinoid receptor: do we have enough evidence? Br J Pharmacol (2014) 0.76
A role for GPR55 in human placental venous endothelial cells. Histochem Cell Biol (2015) 0.75
Epigenetic control of skin differentiation genes by phytocannabinoids. Br J Pharmacol (2013) 0.75
The Histochemistry and Cell Biology omnium-gatherum: the year 2015 in review. Histochem Cell Biol (2016) 0.75
Cannabinoid inhibits HIV-1 Tat-stimulated adhesion of human monocyte-like cells to extracellular matrix proteins. Life Sci (2014) 0.75
CB2 and GPR55 Receptors as Therapeutic Targets for Systemic Immune Dysregulation. Front Pharmacol (2016) 0.75
G protein-coupled receptor GPR55 promotes colorectal cancer and has opposing effects to cannabinoid receptor 1. Int J Cancer (2017) 0.75
Big conductance calcium-activated potassium channel openers control spasticity without sedation. Br J Pharmacol (2017) 0.75
VA opsin-based photoreceptors in the hypothalamus of birds. Curr Biol (2009) 2.01
Ancient colour vision: multiple opsin genes in the ancestral vertebrates. Curr Biol (2003) 1.85
A mitochondria-targeted S-nitrosothiol modulates respiration, nitrosates thiols, and protects against ischemia-reperfusion injury. Proc Natl Acad Sci U S A (2009) 1.78
Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med (2007) 1.69
Evolution and spectral tuning of visual pigments in birds and mammals. Philos Trans R Soc Lond B Biol Sci (2009) 1.56
EDHF: spreading the influence of the endothelium. Br J Pharmacol (2011) 1.54
The therapeutic potential of cannabis. Lancet Neurol (2003) 1.49
Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. Br J Pharmacol (2002) 1.41
Vasodilator actions of abnormal-cannabidiol in rat isolated small mesenteric artery. Br J Pharmacol (2003) 1.37
The influence of ontogeny and light environment on the expression of visual pigment opsins in the retina of the black bream, Acanthopagrus butcheri. J Exp Biol (2008) 1.19
A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis. Am J Pathol (2005) 1.04
Vasorelaxant activities of the putative endocannabinoid virodhamine in rat isolated small mesenteric artery. J Pharm Pharmacol (2004) 1.04
Endothelium-independent relaxation to cannabinoids in rat-isolated mesenteric artery and role of Ca2+ influx. Br J Pharmacol (2003) 1.03
The evolution of early vertebrate photoreceptors. Philos Trans R Soc Lond B Biol Sci (2009) 1.01
Spectral tuning of shortwave-sensitive visual pigments in vertebrates. Photochem Photobiol (2007) 1.01
In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake. Eur J Pharmacol (2004) 0.96
Anandamide reduces infarct size in rat isolated hearts subjected to ischaemia-reperfusion by a novel cannabinoid mechanism. Br J Pharmacol (2005) 0.95
Visual pigments of the platypus: a novel route to mammalian colour vision. Curr Biol (2007) 0.95
Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J (2006) 0.94
An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination, axonal and neuronal loss. J Neuroimmunol (2008) 0.93
Cone visual pigments in two marsupial species: the fat-tailed dunnart (Sminthopsis crassicaudata) and the honey possum (Tarsipes rostratus). Proc Biol Sci (2008) 0.93
Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis. J Neuroimmunol (2007) 0.92
Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis. Mult Scler (2011) 0.91
Vasorelaxant effects of oleamide in rat small mesenteric artery indicate action at a novel cannabinoid receptor. Br J Pharmacol (2006) 0.90
A role for caspase-1 and -3 in the pathology of experimental allergic encephalomyelitis : inflammation versus degeneration. Am J Pathol (2002) 0.90
Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors. Eur J Pharmacol (2002) 0.89
The endocannabinoid system and multiple sclerosis. Curr Pharm Des (2008) 0.85
Characterization of a dominant cone degeneration in a green fluorescent protein-reporter mouse with disruption of Loci associated with human dominant retinal dystrophy. Invest Ophthalmol Vis Sci (2011) 0.84
Epitope spread is not critical for the relapse and progression of MOG 8-21 induced EAE in Biozzi ABH mice. J Neuroimmunol (2005) 0.84
UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders. Eur Neuropsychopharmacol (2005) 0.84
Spectral tuning and evolution of primate short-wavelength-sensitive visual pigments. Proc Biol Sci (2011) 0.83
Paracetamol-induced hypothermia is independent of cannabinoids and transient receptor potential vanilloid-1 and is not mediated by AM404. Drug Metab Dispos (2011) 0.83
Cannabinoids and neuroprotection in CNS inflammatory disease. J Neurol Sci (2005) 0.83
New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis. Br J Pharmacol (2006) 0.83
Endothelium-dependent relaxation and endothelial hyperpolarization by P2Y receptor agonists in rat-isolated mesenteric artery. Br J Pharmacol (2003) 0.82
Genetic background can result in a marked or minimal effect of gene knockout (GPR55 and CB2 receptor) in experimental autoimmune encephalomyelitis models of multiple sclerosis. PLoS One (2013) 0.81
Focus on molecules: centrosomal protein 290 (CEP290). Exp Eye Res (2010) 0.81
The therapeutic potential of cannabis in multiple sclerosis. Expert Opin Investig Drugs (2003) 0.80
Developmental dynamics of cone photoreceptors in the eel. BMC Dev Biol (2009) 0.80
Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis. Brain (2013) 0.80
Neurofilament a biomarker of neurodegeneration in autoimmune encephalomyelitis. Autoimmunity (2012) 0.79
Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis. Acta Neuropathol Commun (2013) 0.79
Visual pigments in a living fossil, the Australian lungfish Neoceratodus forsteri. BMC Evol Biol (2007) 0.78
Encephalitogenic and tolerogenic potential of altered peptide ligands of MOG and PLP in Biozzi ABH mice. J Neuroimmunol (2005) 0.78
Mechanisms of vasorelaxation induced by oleoylethanolamide in the rat small mesenteric artery. Eur J Pharmacol (2013) 0.78
Changes in CB1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice. Brain Res (2006) 0.78
In vivo gene expression: DNA electrotransfer. Curr Opin Mol Ther (2003) 0.77
Characterization of immune response to neurofilament light in experimental autoimmune encephalomyelitis. J Neuroinflammation (2013) 0.76
Latency can be conferred to a variety of cytokines by fusion with latency-associated peptide from TGF-β. Expert Opin Drug Deliv (2013) 0.75